DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer

Not Applicable

Recruiting

Conditions: Stress
Anxiety

Interventions: Behavioral: mPRISM Program App
Behavioral: PRISM Program Video Coach
Behavioral: PRISM Program Text Coach

First Posted Date: 2023-09-14

Last Posted Date: 2024-11-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 325

Registration Number: NCT06038318

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

Not Applicable

Recruiting

Conditions: Lung Cancer

Interventions: Behavioral: Moderate-Intensity Continuous Training (MICT)
Behavioral: High-Intensity Interval Training (HIIT)

First Posted Date: 2023-09-06

Last Posted Date: 2025-01-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT06026111

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2

Active, not recruiting

Conditions: Early-stage Breast Cancer
Breast Cancer
High Risk Breast Carcinoma

Interventions: Drug: Abemaciclib
Drug: Tamoxifen
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: LHRH Agonist

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 90

Registration Number: NCT06001762

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States
🇺🇸
New England Cancer Specialists, Scarborough, Maine, United States

and more 9 locations

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Phase 2

Recruiting

Conditions: Lung Diseases
Bronchiolitis Obliterans
Chronic Graft Versus Host Disease
Bronchiolitis Obliterans Syndrome

Interventions: Drug: Belumosudil
Drug: Fluticasone
Drug: Azithromycin
Drug: Prednisone
Drug: Montelukast

First Posted Date: 2023-06-28

Last Posted Date: 2024-08-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT05922761

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Not Applicable

Recruiting

Conditions: Prostate Cancer
Prostatic Neoplasms

Interventions: Behavioral: High-Intensity Interval Training Exercise Program

First Posted Date: 2023-06-26

Last Posted Date: 2025-02-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 68

Registration Number: NCT05918263

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Not Applicable

Recruiting

Conditions: Penile Cancer
Urologic Cancer
Prostate Cancer
Testicular Cancer
Urologic Neoplasms
Kidney Cancer
Bladder Cancer
Urethral Cancer

Interventions: Device: Electromagnetic Guided Laparoscopy
Device: Ultrasound

First Posted Date: 2023-06-12

Last Posted Date: 2023-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT05899361

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Insomnia Prevention in Children With Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: Leukemia
Acute Lymphoblastic Leukemia
Pediatric Acute Lymphoblastic Leukemia

Interventions: Behavioral: Sleep ALL Night

First Posted Date: 2023-05-19

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT05866887

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Development and Testing of Nutritional Algorithms (NACHO)

Not Applicable

Not yet recruiting

Conditions: Nutrition Poor
Nutritional Deficiency
Quality of Life

Interventions: Behavioral: Nutrition Algorithm

First Posted Date: 2023-04-24

Last Posted Date: 2024-12-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 130

Registration Number: NCT05825469

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Implantable Microdevice for TNBC - Pilot Study

Phase 1

Withdrawn

Conditions: Breast Cancer Stage III
Early Stage Triple-Negative Breast Carcinoma
Breast Neoplasms
Triple Negative Breast Cancer
Breast Cancer
Breast Carcinoma
Breast Cancer Stage II

Interventions: Combination Product: Implantable Microdevice (IMD)

First Posted Date: 2023-03-20

Last Posted Date: 2023-05-18

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT05774886

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Phase 2

Recruiting

Conditions: Multiple Myeloma
Smoldering Multiple Myeloma

Interventions: Drug: Ciltacabtagene Autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2023-03-14

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT05767359

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy